RxDoctor Payments Data

Edward Zoltan, MD

Urology · Brooklyn, NYNPI 1982760302

Payments from drug & device makers

$7,161in general payments, 2019–2025

Across 96 payments — averaging $74.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acerus Pharmaceuticals Corporation$4K
  • Axonics, Inc.$1K
  • Astellas Pharma US Inc$476
  • Neotract Inc.$374
  • Boston Scientific$341
  • Teleflex LLC$219
  • plus $557 from 13 others

What the payments were for

  • Consulting fees$3,00042%
  • Speaking & faculty fees$1322%
  • Travel & lodging$1,21617%
  • Food & beverage$2,62837%
  • Education$1853%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,161 in reported general payments places this provider in the 70th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$415,726
Medicare patients
696
Services billed
5,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate126$721,149
GemtesaVibegron258$157,015
XtandiEnzalutamide11$154,193
MyrbetriqMirabegron170$106,625
MounjaroTirzepatide14$14,436
Alfuzosin Hcl ErAlfuzosin Hcl523$12,772
Finasteride987$12,613
Solifenacin Succinate205$10,392
Trospium Chloride ErTrospium Chloride45$10,080
Tamsulosin Hcl752$9,458
Silodosin71$8,910
Potassium Citrate ErPotassium Citrate131$7,158
Testosterone18$5,617
Tolterodine Tartrate ErTolterodine Tartrate61$4,624
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl22$4,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLupron Depot$22$721,149126 claims
Astellas Pharma US IncXtandi, Myrbetriq$476$260,818181 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 952 urology providers in New York.

Other urology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →